121-02-8

Basic information

• Product Name: 2-Methyl-5-nitrobenzenesulfonyl chloride
• Synonyms: 4-nitrotoluen-2-sulfochlorid;4-nitrotoluen-2-sulfonylchlorid;5-nitro-o-toluenesulfonylchlorid;5-NITRO-O-TOLUENESULFONYL CHLORIDE;2-METHYL-5-NITROBENZENE-1-SULFONYL CHLORIDE;2-METHYL-5-NITROBENZENESULFONYL CHLORIDE;2-METHYL-5-NITROBENZENESULPHONYL CHLORIDE;2-METHYL-5-NITROPHENYLSULFONYL CHLORIDE
• CAS NO: 121-02-8
• Molecular Formula: C₇H₆ClNO₄S
• Molecular Weight: 235.64
• EINECS: 204-444-8
• Product Categories: Benzene derivates;Organic Building Blocks;Sulfonyl Halides;Sulfur Compounds;Aromatics;Intermediates;Sulfur & Selenium Compounds;Building Blocks;Chemical Synthesis;Organic Building Blocks;Sulfonyl Halides;Sulfur Compounds
• Mol File: 121-02-8.mol
• Article Data: 18

Chemical Properties

• Melting Point: 43 °C
• Boiling Point: 135-137°C/0.7mm
• Flash Point: 135-137°C/0.7mm
• Appearance: /
• Density: 1.4103 (rough estimate)
• Vapor Pressure: 2.57E-05mmHg at 25°C
• Refractive Index: 1.6000 (estimate)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: soluble in Toluene
• Sensitive: Moisture Sensitive
• BRN: 2697079
• CAS DataBase Reference: 2-Methyl-5-nitrobenzenesulfonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methyl-5-nitrobenzenesulfonyl chloride(121-02-8)
• EPA Substance Registry System: 2-Methyl-5-nitrobenzenesulfonyl chloride(121-02-8)

Safety Data

• Hazard Codes: C
• Statements: 14-29-34
• Safety Statements: 22-26-30-45-8-36/37/39
• RIDADR: 3261
• WGK Germany: 3
• RTECS: XT8000000
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 121-02-8(Hazardous Substances Data)

Usage

Uses

Intermediate in the preparation of PDE7 inhibitors and kinase inhibitors.

InChI:InChI=1/C7H6ClNO4S/c1-5-2-3-6(9(10)11)4-7(5)14(8,12)13/h2-4H,1H3

Upstream product

• 99-55-8 2-methyl-5-nitroaniline 
• 75-15-0 carbon disulfide 
• 7446-70-0 aluminium trichloride 
• 453-53-2 4-nitro-toluene-2-sulfonyl fluoride 
• 99-99-0 1-methyl-4-nitrobenzene 

Downstream Products

• 110146-30-0 2-methyl-5-nitro-benzenesulfonic acid-[(2-hydroxy-ethyl)-[1]naphthyl-amide] 
• 67320-39-2 N-(4-nitro-toluene-2-sulfonyl)-glycine 
• 91215-03-1 4-(2-methyl-5-nitro-benzenesulfonyl)-morpholine 
• 463314-88-7 2-(2'-methyl-5'-nitrobenzenesulfonyl)-L-glutamic acid 
• 945619-40-9 N'-((6-bromoimidazo[1,2-a]pyridin-3-yl)methylene)-2-methyl-5-nitrobenzenesulfonohydrazide 
• 94464-23-0 4-nitro-trans-stilbene-2-sulfonic acid anilide 
• 197960-17-1 5-methyl-3-(2-methyl-5-nitrophenylsulfonyloxy)phenol 
• 123617-72-1 2-methyl-1-(2-methyl-5-nitro-phenylsulphonyl)-imidazole 
• 1374832-49-1 6-(N₃-phenylureido)saccharin 
• 1374832-51-5 6-(N₃-(3-methoxyphenyl)ureido)saccharin 
• 1374832-53-7 6-(N₃-(4-methoxyphenyl)ureido)saccharin 
• 1374832-55-9 6-(N₃-(4-methylphenyl)ureido)saccharin 
• 1374832-57-1 6-(N₃-(3-chlorophenyl)ureido)saccharin 
• 1374832-59-3 6-(N₃-(4-chlorophenyl)ureido)saccharin 

Relevant articles and documents

Synthesis of some bisnitrosaccharins

Method for synthesis of previously unknown bisnitrosaccharins from 6-nitrosaccharin under the action of bishalide compounds in polar aprotic solvents in the presence of anhydrous potassium carbonate is suggested. Pleiades Publishing, Ltd., 2012.

BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF

The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof. The provided compounds may be tumor necrosis factor ("TNF") receptor associated protein 1 ("TRAP1") modulators (e.g., TRAP1 activators). The provided compounds may also rescue the activity in PTEN-induced kinase 1 ("PINK1") loss of function contexts. The provided compounds may also improve mitochondrial health, function, quality, quantity, and/or activity, and/or reduce the production of reactive oxygen species. The provided compounds may also refold or solubilize aggregated or misfolded proteins such as α-synuclein. The present disclosure also provides pharmaceutical compositions comprising the provided compounds; kits comprising the provided compounds or pharmaceutical compositions; and methods of using the provided compounds and pharmaceutical compositions (e.g., for treating a disease in a subject in need thereof).

Preparation method of 2-methyl-5-aminobenzenesulfonamide

The invention relates to a preparation method of 2-methyl-5-aminobenzenesulfonamide. The preparation method includes following steps: S1, allowing sulfonation: dissovling p-nitrotoluene and chlorosulfonic acid in an organic solvent I, stirring for reaction, and performing aftertreatment to obtain 2-methyl-5-nitrobenzene sulfonyl chloride; S2, allowing hydrogenation and addition: adding 2-methyl-5-nitrobenzene sulfonyl chloride obtained in the S1 into a hydrogenation kettle, sequentially adding a catalyst, ammonia water and an organic solvent II, allowing reaction at high temperature and high pressure, treating after reaction to obtain 2-methyl-5-aminobenzenesulfonamide which is light yellow solid. The preparation method has the advantages of short route, high product purify and easiness for industrial production.